Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

D5 Dopamine Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the Dopamine Receptor 5 in transfected HEK293 cells
D5 (non-phospho), Dopamine Receptor 5 Antibody
The non-phospho-Dopamine Receptor 5 Antibody is directed against the distal end of the carboxyl-terminal tail of human D5. It can be used to detect total D5 receptors in Western blots independent of phosphorylation. The non-phospho-D5...
$ 375.00 *
Details
NEW
Agonist-induced Threonine382/Threonine386 phosphorylation of the Dopamine Receptor 5
pT382/pT386-D5 (phospho-Dopamine Receptor 5...
Threonine382/Threonine386 (T382/T386) is a major phosphorylation site of the D5 receptor. The pT382/pT386-D5 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T382/T386...
$ 375.00 *
Details
NEW
Immunohistochemical identification of Dopamine Receptor 5 in human cortex
D5 (IHC-grade), Dopamine Receptor 5 Antibody
The D5 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human D5. It can be used to detect total D5 receptors in Western blots independent of phosphorylation. The D5 antibody can also be used to...
$ 375.00 *
Details

D5

The dopamine D₅ receptor (D₅R), encoded by DRD5, is a class A G protein-coupled receptor of the D₁-like subfamily. Its endogenous agonist is dopamine, which generally binds D₅R with higher affinity than D₁R in recombinant systems. D₅R couples primarily to Gs-family proteins, stimulating adenylyl cyclase and increasing intracellular cAMP. Receptor expression has been reported in the hippocampus, cerebral cortex, and hypothalamus, as well as in peripheral tissues such as the kidney. Experimental studies implicate D₅R in neuronal excitability and in the regulation of renal sodium handling and blood pressure. Recombinant D₅R can exhibit constitutive activity, while the mechanisms governing its desensitization and trafficking in native tissues remain incompletely characterized. Tavapadon, an oral partial agonist at both D₁ and D₅ receptors, is approved in the United States for the treatment of adults with Parkinson’s disease. No drug selective for D₅R over D₁R is currently approved for therapeutic use. D5 desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine382/threonine386 (pT382/pT386-D5). This nomenclature refers to the human D5. For more information on D5 receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Undieh AS. Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther. 2010 Oct;128(1):37-60. doi: 10.1016/j.pharmthera.2010.05.003. Epub 2010 Jun 12. PMID: 20547182; PMCID: PMC2939266.

Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. PMID: 21303898.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015 Jan;172(1):1-23. doi: 10.1111/bph.12906. PMID: 25671228; PMCID: PMC4280963.

The dopamine D₅ receptor (D₅R), encoded by DRD5 , is a class A G protein-coupled receptor of the D₁-like subfamily. Its endogenous agonist is dopamine, which generally binds D₅R with higher... read more »
Close window
D5 Dopamine Receptor Antibodies

D5

The dopamine D₅ receptor (D₅R), encoded by DRD5, is a class A G protein-coupled receptor of the D₁-like subfamily. Its endogenous agonist is dopamine, which generally binds D₅R with higher affinity than D₁R in recombinant systems. D₅R couples primarily to Gs-family proteins, stimulating adenylyl cyclase and increasing intracellular cAMP. Receptor expression has been reported in the hippocampus, cerebral cortex, and hypothalamus, as well as in peripheral tissues such as the kidney. Experimental studies implicate D₅R in neuronal excitability and in the regulation of renal sodium handling and blood pressure. Recombinant D₅R can exhibit constitutive activity, while the mechanisms governing its desensitization and trafficking in native tissues remain incompletely characterized. Tavapadon, an oral partial agonist at both D₁ and D₅ receptors, is approved in the United States for the treatment of adults with Parkinson’s disease. No drug selective for D₅R over D₁R is currently approved for therapeutic use. D5 desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine382/threonine386 (pT382/pT386-D5). This nomenclature refers to the human D5. For more information on D5 receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Undieh AS. Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther. 2010 Oct;128(1):37-60. doi: 10.1016/j.pharmthera.2010.05.003. Epub 2010 Jun 12. PMID: 20547182; PMCID: PMC2939266.

Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. PMID: 21303898.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015 Jan;172(1):1-23. doi: 10.1111/bph.12906. PMID: 25671228; PMCID: PMC4280963.

Recently viewed